
==== Front
RMD Open
RMD Open
rmdopen
rmdopen
RMD Open
2056-5933
BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR

39214611
10.1136/rmdopen-2024-004308
rmdopen-2024-004308
Clinical Case
Treatments
1506
Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series
http://orcid.org/0009-0002-2611-5562
Li Yuanteng Jeff 1yli61@mdanderson.org

Msaouel Pavlos 2PMsaouel@mdanderson.org

Campbell Matthew 2mcampbell3@mdanderson.org

Hwu Patrick 3patrick.hwu@moffitt.org

Diab Adi 3adiab@mdanderson.org

http://orcid.org/0000-0003-0926-1840
Kim Sang T. 14sangtaek.kim@yale.edu

1 General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2 Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
3 Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
4 Rheumatology, Allergy, and Immunology, Yale University School of Medicine, New Haven, Connecticut, USA
DrSang T.Kim; sangtaek.kim@yale.edu
None declared.

2024
30 8 2024
10 3 e00430807 3 2024
30 7 2024
Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Abstract

Background

Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with cancer. However, these therapies are associated with adverse events including de novo immune-related adverse events or flare of pre-exiting autoimmune disorders. Up to 80% of patients with cancer and pre-existing psoriasis (PsO) or psoriatic arthritis (PsA) experience PsO/PsA flare after initiating ICIs. Targeting the interleukin (IL)-17/IL-23 axis is a mainstream of the PsO/PsA treatment. However, whether this treatment can effectively control PsO/PsA with ICI exposure while preserving anti-tumour efficacy remains unknown.

Case reports

We report three patients with PsA and cancer, who received ICIs for their cancer treatment. All patients were male. Two patients had clear cell renal cell carcinoma, and one had melanoma. Two patients received anti-PD-1 antibody monotherapy, while one patient received combined anti-CTLA-4 and PD-1 antibody therapy. One patient had been receiving anti-IL-17A antibody (secukinumab), while the other two patients started anti-IL-17A antibody (ixekizumab) and anti-IL-23 antibody (guselkumab) after their PsA flared up during ICI treatment. Of note, with the anti-IL-17A or anti-IL-23 antibody treatment, their PsA remained in remission, and they well tolerated the ICI therapy. Importantly, all three patients showed persistent tumour responses to ICI therapy, including two complete remissions and one stable disease, respectively.

Conclusions

These three cases suggest that targeting the IL-17/23 axis may be an effective and safe approach for patients with cancer and pre-existing PsA being considered for ICI therapy.

arthritis, psoriatic
T-lymphocytes
cytokines
http://dx.doi.org/10.13039/100001634 Gateway for Cancer Research http://dx.doi.org/10.13039/100012287 Andrew Sabin Family Foundation http://dx.doi.org/10.13039/100006260 Rheumatology Research Foundation 1012231 http://dx.doi.org/10.13039/100003064 Kidney Cancer Association Advanced Discovery Award http://dx.doi.org/10.13039/100000069 National Institute of Arthritis and Musculoskeletal and Skin Diseases K08AR079587 http://dx.doi.org/10.13039/100000090 Congressionally Directed Medical Research Programs KC200096P1 the University of Texas MD Anderson Cancer Center Division of Internal Medicine IOTOX program Philanthropic donation (Mike and Mary Allen Family Physician-Scientist Award V foundation Translational Research Award
==== Body
pmcWHAT IS ALREADY KNOWN ON THIS TOPIC

WHAT THIS STUDY ADDS

The efficacy of targeting the IL-23/IL-17 axis for PsO/PsA while maintaining anti-tumour immunity mediated by ICIs remains uncertain. Our case series suggests that for patients with PsO/PsA and concomitant cancer necessitating ICIs, targeting the IL-23/IL-17 axis could present an effective approach to manage PsO/PsA without compromising the anti-tumour efficacy of ICIs.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

Consideration of agents targeting the IL-23/IL-17 axis is warranted for the management of PsO/PsA in patients with concurrent cancer necessitating ICIs. However, due to the limited number of patients in this study, further research involving a larger number of patients is needed to substantiate and validate these observations.

Introduction

Targeting T cell-inhibitory molecules including cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed death-1 (PD-1), immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy.1 However, ICIs are often associated with adverse events, distinct from conventional chemotherapies and radiotherapies, including de novo immune-related adverse events (irAEs) and flares of pre-existing autoimmune diseases (ADs).2 Up to 80% of cancer patients with psoriasis (PsO) and psoriatic arthritis (PsA) have PsO/PsA flares following the initiation of ICIs.3

Interleukin (IL)−17, mainly produced by T helper (Th) 17 cells, play a pivotal role in host defence against extracellular pathogens by recruiting neutrophils to the inflamed tissues and enhancing angiogenesis.4 IL-23 stabilises Th17 cells but also induces the Th17 cells to adopt a pathogenic phenotype.4 Pathogenic Th17 cells play a critical role in numerous ADs, particularly PsO and PsA.

While agents targeting the IL-23/IL-17 axis are used for the treatment of PsO and PsA,4 it is unknown whether they are effective for patients with cancer and pre-existing PsO/PsA, who receive ICIs. Here, we report three cases of melanoma (n=1) and renal cell carcinoma (n=2) with pre-existing PsA. One patient had initiated treatment with the anti-IL-17A antibody (secukinumab) before the initiation of ICI therapy, while the other two patients were started on the anti-IL-17A antibody (ixekizumab) or the anti-IL-23 antibody (guselkumab) after they experienced PsA flares following ICI exposure. PsA of all patients remained under control with IL-23/IL-17 blockades. Importantly, all of them achieved durable anti-tumour responses to the ICIs.

Case report

Case 1

Our first case is a 72-year-old male with a history of PsA, osteoarthritis (OA) and metastatic melanoma. The patient was diagnosed with PsA in his 30s and treated with methotrexate (discontinued in few years due to loss of efficacy), etanercept and ultraviolet therapy. He was diagnosed with melanoma at the age of 65, and etanercept was discontinued. The patient was treated with Mohs surgery (figure 1A). Two years later, his melanoma recurred to the lungs, which was treated with surgery and radiation. The patient had PsA flares every few weeks, and few months later, to better control his PsA, secukinumab (150 mg every 4 weeks subcutaneous) was initiated. With secukinumab, his PsA was relatively well controlled with 1–2 times mild flares annually. Four years later, he was found to have lesions in his oesophagus, which were treated with proton therapy, and subsequent immunotherapy was planned. The patient was referred to the rheumatology clinic before administering the anti-PD-1 antibody (pembrolizumab). At the initial rheumatology visit, he was asymptomatic, and his physical examination was unremarkable. Given his 5 year history of secukinumab treatment and the potential impact of its discontinuation on anti-tumour immunity, alongside the risk of ICI-induced PsA flare with undesired usage of steroids,3 after the meeting with the multi-disciplinary team, the decision was made to continue secukinumab. Two weeks after the initial rheumatology evaluation, pembrolizumab was initiated. Four weeks after the first cycle of pembrolizumab, he developed neuritis-irAE that warranted intravenous immunoglobulins and plasmapheresis. At 4 and 7 months after the initiation of pembrolizumab, the patient developed PsA flares that were treated with a short course of prednisone while continuing secukinumab. At 10 months, the patient underwent bilateral knee replacements for his OA, and secukinumab was on hold while continuing low-dose prednisone (5 mg daily). At 20 months, secukinumab was resumed, and prednisone was tapered off at 32 months. The patient successfully completed pembrolizumab and proton therapy to the oesophageal metastases. At the last rheumatology clinic visit, 32 months after the initiation of pembrolizumab, his psoriatic arthritis was under control and melanoma was in remission (figure 1B).

Figure 1 (A) Clinical course of case 1. We defined the date of the first cycle of pembrolizumab as Day 0. Mets, metastasis; irAE, immune-related adverse events; PLEX, plasmapheresis; PsA, psoriatic arthritis; PtGA, patient global assessment (0–10); PGA, physician global assessment (0–10); Mo, month; Pembro, pembrolizumab; IVIg, intravenous immunoglobulin. (B) PET images at baseline and month 32. The oesophageal lesion at baseline (indicated by the arrow) was completed resolved at month 32.

Case 2

Our second case is a 47-year-old man with PsA and clear cell renal cell carcinoma (ccRCC). The patient was diagnosed with PsA in his 40s. Adalimumab was started, and his PsA was brought under control. However, 3 years later, he was diagnosed with left-sided ccRCC and treated with partial nephrectomy (figure 2A). Adalimumab was also discontinued. One month later, he was found to have metastases to the brain that were treated with radiation therapy. His cancer aggressively progressed despite of two tyrosine kinase inhibitor (TKI)-based regimens. Subsequently, he referred to the rheumatology clinic before starting pembrolizumab in combination with the TKI (axitinib). At his initial rheumatology evaluation, the patient did not exhibit active PsA symptoms, and physical exam was unremarkable. As his PsA was in remission, the decision was made to hold any immunosuppressive medications. One week later, pembrolizumab and axitinib were initiated. In month 7, he developed PsO as well as PsA flare. Given the aggressive nature of his ccRCC and negative impacts of steroids on ICI-efficacy,5 6 a steroid-sparing agent was warranted to minimise the use of steroids. From rheumatologic perspectives, since his PsO and PsA were both flared, disease-modifying antirheumatic drugs (DMARDs) were also indicated. Among the DMARDs for PsO/PsA,7 methotrexate and apremilast were relatively contraindicated due to his nephrectomy status. Janus kinase inhibitors (JAKi) were not preferred because of their potential negative impact on anti-tumour immunity. Subsequently, ixekizumab (160 mg subcutaneous once followed by 80 mg every 4 weeks subcutaneous) was initiated along with a short course of prednisone, while pembrolizumab and axitinib were continued. Two months later, he was found to have new brain metastases on routine monitoring. Given the persistently excellent extracranial control of the metastatic ccRCC, he remained on pembrolizumab, axitinib and ixekizumab while receiving gamma knife radiotherapy to the new brain lesions. At the most recent rheumatology clinic visit, 22 months after the initiation of pembrolizumab plus axitinib, his PsA remains well controlled with ixekizumab monotherapy. He continues his pembrolizumab and axitinib treatment. Most recent images demonstrated persistent response of the ccRCC with no evidence of recurrent brain metastases (figure 2B).

Figure 2 (A) Clinical course of case 2. We defined the date of the first cycle of pembrolizumab as Day 0. Mets, metastasis; PsA, psoriatic arthritis; PsO, psoriasis; PtGA, patient global assessment (0–10); PGA, physician global assessment (0–10); Mo, month. (B) CT images at baseline and month 26. Note the complete resolution of the hepatic and right gluteal lesions (indicated by arrows) and the stable lesion in the left acetabulum (indicated by the arrowhead) at month 26.

Case 3

Our third case is a 60-year-old male with PsA, metastatic ccRCC and remote history of melanoma status post excision and cryoablation in remission. The patient developed PsO in his late 30 s and developed inflammatory arthritis about 15 years later and was subsequently started on sulfasalazine. He was diagnosed with ccRCC at the age of 56 for which he underwent left partial nephrectomy (figure 3A). However, his cancer recurred three times, and he was considered for potential ICI therapy with the anti-CTLA-4 antibody (ipilimumab) in combination with the anti-PD-1 antibody (nivolumab). During the initial visit to the rheumatology clinic, he was asymptomatic, and his physical exam was unremarkable. The decision was made to continue sulfasalazine. On the same day, he had the first cycle of ipilimumab and nivolumab. The anti-IL-6 receptor antibody (tocilizumab) was added due to the patient’s history of melanoma and the potential synergic anti-cancer effects of tocilizumab when combined with ICI. Two weeks later, the patient was found to have transaminitis-irAE and thyroiditis-irAE. Tocilizumab was subsequently put on hold. After his transaminitis was resolved, tocilizumab was resumed. However, 1 month later, the patient developed PsA flare that required prednisone. In addition, tocilizumab was also discontinued for potential paradoxical PsA flare. As the patient had difficulty in tapering prednisone for PsA, 1 month later, a decision was made to initiate a DMARD. Like in our second case, methotrexate, apremilast and JAKi were not preferred due to either his nephrectomy status or potential abrogation of ICI efficacy. In addition, we were concerned about the risk of colitis-irAE associated with combined ICI therapy8 and the negative impact of IL-17i on colonic mucosa.9 Therefore, the anti-IL-23 antibody (guselkumab) was initiated (100 mg subcutaneous injection at weeks 0, 4 and then every 8 weeks). The patient responded well to guselkumab and was successfully tapered off prednisone over 3 months while being able to continue his ICI therapy. At the most recent rheumatology clinic visit, 10 months after the initiation of the ICI therapy, his PsA remains well controlled with guselkumab monotherapy. The patient continues his ICI treatment, and images revealed that his ccRCC is in remission (figure 3B).

Figure 3 (A) Clinical course of case 3. We defined the date of the first cycle of ipilimumab and nivolumab as day 0. Mets, metastasis; irAE, immune-related adverse events; PsA, psoriatic arthritis; PtGA, patient global assessment (0–10); PGA, physician global assessment (0–10); Mo, month. (B) CT images at baseline and month 15. The images show complete resolution of the lesion in the hilar region (indicated by the arrow).

Discussion

Although ICIs are revolutionising cancer treatment, they are also associated with life-/organ-threatening adverse events including de novo irAEs and flare of pre-existing ADs. It has been observed that up to 80% of PsO/PsA patients with cancer experience flare of their pre-existing PsO/PsA after ICI therapy.3 In this study, we reported three cases in which PsA was effectively managed with either an anti-IL-17A antibody or an anti-IL-23 antibody. Importantly, the ICI therapy was well tolerated and has produced durable long-term anti-tumoural responses (15, 26 and 32 months after initiation). Of note, a case with ICI-induced PsA successfully managed with IL-23i without compromise of anti-tumour efficacy has also been reported,10 supporting our observations. The role of the IL-23/IL-17 axis in cancer is controversial.11 IL-17 supports tumour growth by prompting tumour angiogenesis12 and activating IL-6/STAT3 pathway in tumour cells, a key pathway in cancer development and progression.13 Likewise, the genetic or pharmacologic depletion of IL-23 has been found to significantly mitigate tumour formation during chemical carcinogenesis by increasing the infiltration of cytotoxic T cells into tumours.14 In contrast, IL-17 assumes an anti-tumorigenic role by prompting cancer cells to secrete CC-chemokine ligand 20, which recruits CC-receptor six expressing dendritic cells (DCs) into the tumour sites.15 IL-17 also stimulates expression of CXC-chemokine ligand 9 (CXCL9) and CXCL10 on tumour cells, which attract anti-tumoral CD8 T cells and Th1 cells.16 Similarly, IL-23 overexpression by DCs, T cells or cancer cells has been shown to enhance anti-tumour immunity.17 Of note, contrary to our patients, a case with PsA and metastatic colon cancer, who lost tumour response to anti-PD-1 antibody with the initiation of anti-IL-17A antibody, has been reported.18 Taken together, clinical, translational and basic research are required to identify risk factors associated with the attenuation of ICI anti-tumour efficacy due to IL-23/17 inhibition.

Our first case had received secukinumab for 5 years before the initiation of ICIs. He experienced two flares, at 4 and 7 months after the initiation of pembrolizumab, suggesting that secukinumab might not have prophylactic benefits for PsA. Studies have shown that the levels of serum pro-inflammatory cytokines such as interferon gamma, IL-1β, IL-4, IL-5, IL-6, IL-8, GM-CSF and TNFα are increased after ICI therapy,19 20 which might have diminished the efficacy of secukinumab; however, this hypothesis needs to be proven. Clinically, our first case suggests that rheumatologists and oncologists should closely monitor co-existing autoimmune diseases regardless of the status of DMARDs before initiatiing ICIs. The prophylactic effects of pre-ICI DMARDs are a critical topic for future research.

Our study has several limitations. Given the limited number of cases, drawing definitive conclusions would be premature. Second, our cases were heterogenous in terms of primary cancer types, ICI regimen and PsA treatment before the ICIs. Third, due to the COVID-19 pandemic, their rheumatologic follow-ups were often conducted virtually, which kept us from assessing PsA disease activity through standard measurements.21 22 Lastly, in case 3, we cannot exclude the possibility that tocilizumab might have contributed to his durable anti-tumour efficacy.

As ICIs increasingly become therapeutic mainstays for multiple malignancies, clinicians will encounter challenging cases, including managing PsO/PsA during ICI therapy. Our case series suggests that targeting the IL-23/IL-17 axis could be a promising therapeutic strategy in this setting. However, with a small number of cases and the controversial role of the IL-23/IL-17 axis in cancer, we cannot make definitive conclusions at this moment. Future studies with larger numbers of patients, standardised measurement of PsO/PsA and concurrent analyses of the patients’ samples are warranted.

Funding: This work was supported by NIH K08 grant (STK: K08AR079587), Rheumatology Research Foundation Fund (STK: 1012231) and the University of Texas MD Anderson Cancer Center (MDACC) Division of Internal Medicine IOTOX program (STK). PM was supported by the Andrew Sabin Family Foundation Fellowship, Gateway for Cancer Research, a Translational Research Partnership Award (KC200096P1) by the United States Department of Defense, an Advanced Discovery Award by the Kidney Cancer Association, a Translational Research Award by the V Foundation, the MD Anderson Physician-Scientist Award, as well as philanthropic donations by the family of Mike and Mary Allen.

Patient consent for publication: Consent obtained directly from patient(s).

Ethics approval: This study involves human participants. We inquired with our institution (MD Anderson) and were informed that case series are deemed 'not human subject research' and do not require IRB-approved protocols. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review: Not commissioned; externally peer reviewed.
==== Refs
References

1 Sharma P Allison JP The future of immune checkpoint therapy Science 2015 348 56 61 10.1126/science.aaa8172 25838373
2 Suarez‐Almazor ME Kim ST Abdel‐Wahab N et al Review: immune‐related adverse events with use of checkpoint inhibitors for immunotherapy of cancer Arthritis Rheumatol 2017 69 687 99 10.1002/art.40043 28085999
3 Abdel-Wahab N Shah M Lopez-Olivo MA et al Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease Ann Intern Med 2018 168 121 10.7326/M17-2073 29297009
4 Lubberts E Erratum: The IL-23–IL-17 axis in inflammatory arthritis Nat Rev Rheumatol 2015 11 562 10.1038/nrrheum.2015.128
5 Faje AT Lawrence D Flaherty K et al High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma Cancer 2018 124 3706 14 10.1002/cncr.31629 29975414
6 Scott SC Pennell NA Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab J Thorac Oncol 2018 13 1771 5 10.1016/j.jtho.2018.06.004 29935305
7 Gossec L Kerschbaumer A Ferreira RJO et al EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update Ann Rheum Dis 2024 83 706 19 10.1136/ard-2024-225531 38499325
8 Som A Mandaliya R Alsaadi D et al Immune checkpoint inhibitor-induced colitis: A comprehensive review World J Clin Cases 2019 7 405 18 10.12998/wjcc.v7.i4.405 30842952
9 Deng Z Wang S Wu C et al IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis Front Pharmacol 2023 14 1124628 10.3389/fphar.2023.1124628 37033665
10 Takeda K Yanagitani N Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis Ann Rheum Dis 2022 annrheumdis-2022-222628 10.1136/annrheumdis-2022-222628
11 Vitiello GA Miller G Targeting the interleukin-17 immune axis for cancer immunotherapy J Exp Med 2020 217 e20190456 10.1084/jem.20190456 31727783
12 Numasaki M Fukushi J Ono M et al Interleukin-17 promotes angiogenesis and tumor growth Blood 2003 101 2620 7 10.1182/blood-2002-05-1461 12411307
13 Wang L Yi T Kortylewski M et al IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway J Exp Med 2009 206 1457 64 10.1084/jem.20090207 19564351
14 Langowski JL Zhang X Wu L et al IL-23 promotes tumour incidence and growth Nature New Biol 2006 442 461 5 10.1038/nature04808
15 Martin-Orozco N Muranski P Chung Y et al T helper 17 cells promote cytotoxic T cell activation in tumor immunity Immunity 2009 31 787 98 10.1016/j.immuni.2009.09.014 19879162
16 Kryczek I Banerjee M Cheng P et al Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments Blood 2009 114 1141 9 10.1182/blood-2009-03-208249 19470694
17 Zou W Restifo NP T(H)17 cells in tumour immunity and immunotherapy Nat Rev Immunol 2010 10 248 56 10.1038/nri2742 20336152
18 Esfahani K Miller WH Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade N Engl J Med 2017 376 1989 91 10.1056/NEJMc1703047 28514612
19 Rossi N Lee KA Bermudez MV et al Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma EBioMedicine 2022 83 104235 10.1016/j.ebiom.2022.104235 36007304
20 Hardy-Werbin M Rocha P Arpi O et al Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer Oncoimmunology 2019 8 e1593810 10.1080/2162402X.2019.1593810 31069160
21 Acosta Felquer ML Ferreyra Garrott L Marin J et al Remission criteria and activity indices in psoriatic arthritis Clin Rheumatol 2014 33 1323 30 10.1007/s10067-014-2626-y 24820142
22 Perruccio AV Got M Li S et al Development of a modified psoriatic arthritis disease activity score using the medical outcomes study short form 12 as a measure of quality of life Arthritis Care Res (Hoboken) 2020 72 577 82 10.1002/acr.23876
